Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TEGISON is an oral small-molecule capsule approved by Roche in 1986 for an undisclosed indication. The exact mechanism of action and therapeutic class are not publicly detailed in available data, limiting assessment of its clinical positioning.
Product is nearing loss of exclusivity with minimal commercial data available; small team sizes likely reflect mature/declining product portfolio status.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings indicate minimal active hiring for TEGISON roles; this reflects a mature product with skeleton crew management. Career engagement with this asset offers limited growth and mobility compared to growth-stage products.
Worked on TEGISON at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.